As of Friday close, Adicet Bio Inc.’s (NASDAQ:ACET) stock was down -$0.1, moving down -5.08 percent to $1.87. The average number of shares traded per day over the past five days has been 482,480 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.4300 fall in that time frame. In the last twenty days, the average volume was 500,795, while in the previous 50 days, it was 1,055,702.
Since last month, ACET stock retreated -36.82%. Shares of the company fell to $1.8700 on 08/18/23, the lowest level in the past month. A 52-week high of $21.87 was reached on 02/02/23 after having rallying from a 52-week low of $1.95. Since the beginning of this year, ACET’s stock price has dropped by -79.08% or -$7.0700, and marked a new high 3 times. However, the stock has declined by -91.45% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ACET stock investors should be aware that Adicet Bio Inc. (ACET) stock had its last reported insider trading activity 50 days ago on Jun 30. DUBIN STEVE, the Director of the company, purchased of 5,000 shares for $2.40 on Jun 30. It resulted in a $12,000 investment by the insider. GORDON CARL L added 875,000 shares at an average price of $2.09 on Jun 27. The insider now owns 5,685,259 shares following the transaction. On Jun 27, Director ORBIMED ADVISORS LLC bought 875,000 shares at $2.09 apiece. The transaction was valued at $1,828,750.
Valuation Metrics
The latest dividend of $0.01 per share was paid out, remained unchanged from last year’s $0.01.
Financial Health
In the three months ended June 29, Adicet Bio Inc.’s quick ratio stood at 11.10, while its current ratio was 11.10, showing that the company is able to pay off its debt. Based on annual data, ACET earned $97.54 million in gross profit and brought in $24.99 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -24.80%. Return on equity (ROE) for the past 12 months was -41.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Adicet Bio Inc. to report -$0.68 quarterly earnings, the actual figure was -$0.75 per share, beating the consensus estimate by -10.30%. During the quarter, the company generated -$33.37 million in EBITDA. The liabilities of Adicet Bio Inc. were 38.57 million at the end of its most recent quarter ended June 29, and its total debt was $22.64 million. The value of shareholders’ equity is $43.07 million.
Technical Picture
This quick technical analysis looks at Adicet Bio Inc.’s (ACET) price momentum. With a historical volatility rate of 78.60%, the RSI 9-day stood at 24.47% on 18 August.
With respect to its five-day moving average, the current Adicet Bio Inc. price is down by -18.70% percent or -$0.4300. At present, ACET shares trade -36.39% below its 20-day simple moving average and -68.41% percent below its 100-day simple moving average. However, the stock is currently trading approximately -67.25% below its SMA50 and -88.66% below its SMA200.
Stochastic coefficient K was 8.43% and Stochastic coefficient D was 10.10%, while ATR was 0.1918. Given the Stochastic reading of 0.00% for the 14-day period, the RSI (14) reading has been calculated as 29.05%. As of today, the MACD Oscillator reading stands at -0.1578, while the 14-day reading stands at -0.2540.
Analyst Ratings
Adicet Bio Inc. downgraded its rating on Adicet Bio Inc. (NASDAQ: ACET) to a Mkt perform in a note to investors on June 27, 2023. The analysts firm previously had a Mkt outperform rating on the stock.Adicet Bio Inc. (ACET) has been rated Overweight by analysts. According to 0 brokerage firms, ACET is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Adicet Bio Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $25.00, the current consensus forecast for the stock is $10.00 – $28.00. Based on these forecasts, analysts predict Adicet Bio Inc. (ACET) will achieve an average price target of $21.00.
